Moderna Inc. ($MRNA) Stock Forecast: Down 5.5% Today

What is Moderna Inc.?

Moderna is a leading biotechnology company known for its innovative mRNA platform, with a focus on developing vaccines and therapies for various diseases.

Why is Moderna Inc. going down?

MRNA stock is down 5.5% on Jun 25, 2026 13:56

• Today's bearish movement for Moderna could be due to profit-taking by investors following the company's Science Day event, where advancements in its mRNA pipeline were showcased without any major breakthroughs or immediate revenue-generating milestones being announced.
• The market's negative reaction may stem from the absence of near-term commercial growth catalysts, as Moderna highlighted a long-term innovation strategy across multiple therapeutic areas like cancer and autoimmune diseases.
• Investor caution might be influenced by the high expectations set by Moderna in diversifying its pipeline and expanding its mRNA platform. This caution has led to a sell-off as investors await more concrete clinical data and revenue projections.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna outlines mRNA pipeline progress at Science Day event

Moderna (NASDAQ: MRNA) presented updates on its research and early development programs at its Science Day event, showcasing advancements in T-cell engagers and a new in vivo CAR-T program. Key highlights include an early clinical signal for mRNA-2808 in multiple myeloma, the progression of mRNA-2151 for ovarian cancer, and the introduction of mRNA-6007 for autoimmune diseases with first-in-human trials expected by late 2027. The company also plans to start a Phase 1/2 study for mRNA-4194 targeting Lynch syndrome and expects Phase 1/2 data for mRNA-1195 in multiple sclerosis in the second half of 2026.

https://www.streetinsider.com/Corporate+News/Moderna+outlines+mRNA+pipeline+progress+at+Science+Day+event/26688046.html

Moderna Science Day Highlights Expanding Potential of mRNA Platform

Moderna's Science Day detailed the company's research and early development programs, emphasizing its strategic shift to become a diversified, multi-modality biotechnology company. The event highlighted advancements in T-cell engager modalities and introduced an in vivo CAR-T modality for autoimmune diseases, aiming to fuel future growth and expand its mRNA platform. Moderna outlined its strategy across three horizons, balancing near-term growth with long-term innovation powered by data, AI, and machine learning.

https://ca.finance.yahoo.com/news/moderna-science-day-highlights-expanding-110000927.html

Moderna says its mRNA pipeline now spans cancer and autoimmune disease

Moderna announced updates at its Science Day, highlighting its mRNA platform's expansion into cancer and autoimmune diseases, beyond its established vaccine franchises. The company is advancing T-cell engagers like mRNA-2808 for multiple myeloma and introducing an in vivo CAR-T program, mRNA-6007, for autoimmune conditions like systemic lupus erythematosus. Moderna's strategy emphasizes balancing near-term commercial growth with long-term innovation across three strategic horizons, leveraging an AI-enabled Scientific Intelligence Engine to accelerate discovery.

https://www.stocktitan.net/news/MRNA/moderna-science-day-highlights-expanding-potential-of-m-rna-2l5j48yhp52b.html

Enterprise value to revenue forward of Moderna, Inc. – NASDAQ:MRNA

This article focuses on the enterprise value to revenue forward for Moderna, Inc. (NASDAQ: MRNA). The content provided by TradingView highlights financial data points for the biotechnology company.

https://www.tradingview.com/symbols/NASDAQ-MRNA/financials-statistics-and-ratios/enterprise-value-sales-fwd/

Kymera taps Felix Baker as board chairman; Booth stays on

Kymera Therapeutics (NASDAQ: KYMR) has appointed Felix J. Baker, PhD, as the new Chairman of its Board of Directors, effective June 24, 2026. He succeeds co-founder Bruce Booth, DPhil, who will remain an Independent Director. Baker has been Kymera's Lead Independent Director since 2024 and leads Baker Brothers Investments, and his appointment is expected to provide experienced leadership as the company advances its oral degrader pipeline.

https://www.stocktitan.net/news/KYMR/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-dmdb4d92toj8.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.7% Today

Gasoline ($GASOLINE) Commodity Forecast: Up 5.0% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 5.1% Today

Wingstop Inc. ($WING) Stock Forecast: Up 5.4% Today

Nasdaq Inc. ($NDAQ) Stock Forecast: Down 5.1% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 5.3% Today

MSCI Inc ($MSCI) Stock Forecast: Down 5.8% Today

Ross Stores Inc. ($ROST) Stock Forecast: Down 5.2% Today

Caterpillar Inc. ($CAT) Stock Forecast: Up 6.2% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 5.9% Today

Moderna Inc. Price History

12.05.2026 - MRNA Stock was up 5.2%

• Moderna's stock rose nearly 8%, in line with Nasdaq's recovery and positive market sentiment.
• Investor interest is high in Moderna's mRNA cancer vaccine pipeline, particularly with the approval of a new trial for mRNA-4194 in Lynch syndrome patients by UK regulators.
• Analysts are recommending a "Hold" on Moderna despite the stock's rise, with an average target price lower than the current closing value.
• The upswing in Moderna's stock may also be linked to a legal conflict with BioNTech regarding patent infringement, with Moderna asserting that its new COVID-19 vaccine does not infringe upon BioNTech's intellectual property, adding an intriguing element to the stock's movement.

16.05.2026 - MRNA Stock was up 5.7%

• Moderna's strong bullish movement today can be attributed to the strategic organizational changes announced by the company, signaling preparations for multiple product launches in 2027 and 2028.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded role of President Stephen Hoge to oversee key operations and product launches have instilled confidence in investors regarding the company's future growth prospects.
• Despite reported wider-than-expected quarterly losses and a consensus "Reduce" rating from analysts, the market seems to be focusing more on the long-term potential of Moderna's upcoming vaccine launches, leading to the positive stock movement.

17.05.2026 - MRNA Stock was up 6.1%

• This company held an Investor Event Science Day to showcase its research and development programs, particularly emphasizing innovation using mRNA technology, which likely boosted investor confidence.
• Collaboration with the FDA for an mRNA flu vaccine and positive developments in the biopharma industry, along with growing interest in biotech IPOs and ongoing industry challenges, contributed to the positive sentiment.
• Stock gains were also influenced by new product releases and advancements in the company's pipeline, strengthening its market position.
• The bullish movement observed today can be attributed to a combination of positive developments, technological advancements, and investor confidence in the biopharma industry.

16.05.2026 - MRNA Stock was up 11.4%

• Moderna's stock surge is linked to the favorable developments related to its mRNA-1010 seasonal flu vaccine. The FDA has shown support for the company's key immunogenicity data, despite some remaining uncertainties.
• Recent changes within Moderna's leadership team, such as the appointment of a new Chief Commercial Officer and expanded roles for key executives, indicate the company's strategic readiness for potential product launches. This has bolstered investor confidence in Moderna's future prospects.
• Verition Fund Management LLC has significantly increased its stake in Moderna, suggesting a growing investor interest in the company. Despite Moderna reporting a wider-than-expected quarterly loss, the positive outlook on the company's upcoming product launches appears to outweigh immediate financial concerns.

16.05.2026 - MRNA Stock was up 9.5%

• Moderna's stock saw a 9.5% surge due to favorable feedback from FDA staff regarding its flu vaccine candidate, mFlusiva, especially on its strong immune response in adults aged 65 and above. This positive development bolstered investor confidence in Moderna's vaccine projects.
• Initially met with some doubts from FDA scientists, the agreement between Moderna and the FDA on immunogenicity data pertaining to older adults before the upcoming advisory committee meeting on June 18th played a pivotal role in the stock's upward trajectory.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded responsibilities of President Stephen Hoge indicate Moderna's strategic groundwork for potential product launches, such as flu and norovirus vaccines, supporting favorable market outlook towards the company.
• The regulatory process concerning Moderna's flu vaccine, with lingering uncertainties on its long-term safety and efficacy for specific demographics, will be a crucial determinant affecting the company's stock performance in the coming period.

17.05.2026 - MRNA Stock was up 10.8%

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

17.05.2026 - MRNA Stock was up 6.3%

• Moderna's market uptick is linked to upbeat investor views following the Investor Event Science Day announcement. The event highlighted the company's research and development efforts, underscoring the potential of its mRNA platform in conjunction with AI and robotics.
• Collaboration with the FDA on its mRNA flu vaccine and the upcoming advisory committee meeting also played a role in the market's positive reaction, suggesting progress in Moderna's pipeline.
• The rise in biotech IPOs and ongoing biopharma sector developments may have contributed to the favorable climate for Moderna's stock, with investors expressing optimism about the industry's growth prospects.
• In general, Moderna's strategic actions, along with positive industry trends, likely drove today's bullish market performance.

18.05.2026 - MRNA Stock was up 5.5%

• Moderna's bullish movement today could be attributed to the company considering acquiring BioNTech's German manufacturing plants. This strategic move not only expands Moderna's production capacity but also positions it favorably in the European market.
• Additionally, the FDA clearance for Beam Therapeutics' BEAM-304 PKU gene-editing trial may have indirectly boosted Moderna's stock, as it highlights the advancements in genetic therapies within the biotech sector.
• The FDA scrutiny of Moderna's mRNA flu vaccine could have also impacted the stock positively, as it demonstrates the company's commitment to expanding its vaccine portfolio beyond COVID-19 solutions.
• Overall, Moderna's proactive approach towards acquisitions, clinical trials, and vaccine development seems to have resonated well with investors, driving the bullish movement in its stock price today.

18.05.2026 - MRNA Stock was up 8.0%

• Moderna's bullish movement can be attributed to the positive news surrounding its mRNA flu vaccine facing FDA scrutiny for approval in older adults. This potential approval would mark a significant milestone for the company, especially in the competitive flu vaccine market.
• The anticipation of Moderna entering the flu vaccine market with its mRNA technology, competing with traditional vaccine companies like Sanofi and GSK, has likely sparked investor optimism and contributed to the bullish trend.
• Investors may view Moderna's innovative approach to vaccine development and its potential expansion into new markets as a positive sign for the company's growth prospects, driving the stock price higher.
• The news of Moderna's mRNA flu vaccine progress overshadowed other headlines in the biotechnology sector, keeping the focus on the company's promising developments and future potential.

23.05.2026 - MRNA Stock was up 6.5%

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

22.05.2026 - MRNA Stock was down 5.2%

• Confirmation of Moderna's mRNA flu vaccine, mRNA-1010, passing the FDA Advisory Committee meeting is viewed positively, notwithstanding concerns about weak operational performance and high valuation.
• Leerink Partners' adjustment of the price target and maintenance of an "Underperform" rating are seen as contributing to the prevailing negative sentiment.
• Despite a recent 6-day streak of gains and a significant increase in market capitalization, worries regarding the company's financial health and valuation being deemed "Very Unattractive" may have overshadowed any positive trend.
• The $2.25 billion settlement with Roivant Sciences could have adversely affected Moderna's stock, despite providing legal clarity, as investors might be wary of its implications on Moderna's finances and future prospects.

25.05.2026 - MRNA Stock was down 5.5%

• Today's bearish movement for Moderna could be due to profit-taking by investors following the company's Science Day event, where advancements in its mRNA pipeline were showcased without any major breakthroughs or immediate revenue-generating milestones being announced.
• The market's negative reaction may stem from the absence of near-term commercial growth catalysts, as Moderna highlighted a long-term innovation strategy across multiple therapeutic areas like cancer and autoimmune diseases.
• Investor caution might be influenced by the high expectations set by Moderna in diversifying its pipeline and expanding its mRNA platform. This caution has led to a sell-off as investors await more concrete clinical data and revenue projections.